D. Martinez-Ramirez, A. Almaraz-Espinoza, Alejandro Banegas-Lagos, P. Bazan-Rodriguez, E. S. Velázquez-Ávila, A. González-Cantú, A. Cervantes-Arriaga, M. Rodríguez‐Violante
{"title":"Association between dopaminergic-induced complications and life satisfaction in ParkinsonÓ?s disease","authors":"D. Martinez-Ramirez, A. Almaraz-Espinoza, Alejandro Banegas-Lagos, P. Bazan-Rodriguez, E. S. Velázquez-Ávila, A. González-Cantú, A. Cervantes-Arriaga, M. Rodríguez‐Violante","doi":"10.24875/rmn.22000046","DOIUrl":"https://doi.org/10.24875/rmn.22000046","url":null,"abstract":"","PeriodicalId":53921,"journal":{"name":"Revista Mexicana de Neurociencia","volume":null,"pages":null},"PeriodicalIF":0.2,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46844344","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Neutrophil to lymphocyte ratio and stroke. What should we know?","authors":"F. Barinagarrementería","doi":"10.24875/rmn.m22000092","DOIUrl":"https://doi.org/10.24875/rmn.m22000092","url":null,"abstract":"","PeriodicalId":53921,"journal":{"name":"Revista Mexicana de Neurociencia","volume":null,"pages":null},"PeriodicalIF":0.2,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49004688","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Renata Murguiondo-Pérez, Ó. V. Alcántar-Garibay, Efraín Weintraub Ben-Zión, Enrique Blancarte-Hernández, Emilio Tejerina-Marion, Ericka Cristina Loza-López, Mario Galindo-Ruiz, Germán Rivera-Monroy
Neurodegenerative diseases (NDDs) are a global health problem that has been on the rise in recent years. Reviewing the definition of neurodegeneration, it can be established that NDDs are not only chronic diseases since acute events can also generate neurodegeneration. Recent research has focused on identifying key factors in the development of NDDs in order to generate new therapies at different levels of the pathophysiology of these diseases. The relationship between the gut microbiota and neuroinflammation has been subject of research in recent years, discovering new linking and triggering processes. In this text, we seek to summarize the existing findings regarding three NDDs (Alzheimer’s disease, Parkinson’s disease, and Stroke) and their relationship with the Gut Brain Axis, as well as highlight the importance of maintaining a healthy microbiota and generating therapies focused on reducing gut inflammation for the management of NDDs.
{"title":"The influence of gut brain axis in neurodegenerative diseases: short review","authors":"Renata Murguiondo-Pérez, Ó. V. Alcántar-Garibay, Efraín Weintraub Ben-Zión, Enrique Blancarte-Hernández, Emilio Tejerina-Marion, Ericka Cristina Loza-López, Mario Galindo-Ruiz, Germán Rivera-Monroy","doi":"10.24875/rmn.210000821","DOIUrl":"https://doi.org/10.24875/rmn.210000821","url":null,"abstract":"Neurodegenerative diseases (NDDs) are a global health problem that has been on the rise in recent years. Reviewing the definition of neurodegeneration, it can be established that NDDs are not only chronic diseases since acute events can also generate neurodegeneration. Recent research has focused on identifying key factors in the development of NDDs in order to generate new therapies at different levels of the pathophysiology of these diseases. The relationship between the gut microbiota and neuroinflammation has been subject of research in recent years, discovering new linking and triggering processes. In this text, we seek to summarize the existing findings regarding three NDDs (Alzheimer’s disease, Parkinson’s disease, and Stroke) and their relationship with the Gut Brain Axis, as well as highlight the importance of maintaining a healthy microbiota and generating therapies focused on reducing gut inflammation for the management of NDDs.","PeriodicalId":53921,"journal":{"name":"Revista Mexicana de Neurociencia","volume":null,"pages":null},"PeriodicalIF":0.2,"publicationDate":"2022-11-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47133811","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Objective: The objective of the study was to know the opinion and prevalence of use of central nervous system stimulant drugs (SDs) in healthy people in open population. Methods: An electronic survey was designed with 11 questions to know the frequency of use of SD, and also questions to explore previous knowledge, opinion about the risks associated with its use and about its regulation, etc. The survey was spread by electronic social networks to persons over 18 years old of any gender. Descriptive analysis and a Chi-square test were done to find associations between variables. Results: A total of 526 surveys were conducted, 271 male participants (51.5%) and 249 female (47.3%). The median of age was 22 years old (range 18-83 years). Median scholarship was 12 years (range 6-20 years). About 49.6% were students. About 75% had prior knowledge about stimulants, 13.6% reported prior use, 26% opined these drugs could be dangerous, and 88% opined that they should be regularized. Finally, ages between 18 and 30 years old and scholarship above high school were associated with the use of SD. Conclusion: There was a frequency of 13.6% of SD use. Most of the respondents are worried about its safety and are in favor of their regularization. Being young with high scholarship was associated with SD use.
{"title":"Opinion and prevalence of use of central nervous system stimulants in open population: results of an electronic survey","authors":"Paulina Flores-Medina, P. Carrillo-Mora","doi":"10.24875/rmn.220000031","DOIUrl":"https://doi.org/10.24875/rmn.220000031","url":null,"abstract":"Objective: The objective of the study was to know the opinion and prevalence of use of central nervous system stimulant drugs (SDs) in healthy people in open population. Methods: An electronic survey was designed with 11 questions to know the frequency of use of SD, and also questions to explore previous knowledge, opinion about the risks associated with its use and about its regulation, etc. The survey was spread by electronic social networks to persons over 18 years old of any gender. Descriptive analysis and a Chi-square test were done to find associations between variables. Results: A total of 526 surveys were conducted, 271 male participants (51.5%) and 249 female (47.3%). The median of age was 22 years old (range 18-83 years). Median scholarship was 12 years (range 6-20 years). About 49.6% were students. About 75% had prior knowledge about stimulants, 13.6% reported prior use, 26% opined these drugs could be dangerous, and 88% opined that they should be regularized. Finally, ages between 18 and 30 years old and scholarship above high school were associated with the use of SD. Conclusion: There was a frequency of 13.6% of SD use. Most of the respondents are worried about its safety and are in favor of their regularization. Being young with high scholarship was associated with SD use.","PeriodicalId":53921,"journal":{"name":"Revista Mexicana de Neurociencia","volume":null,"pages":null},"PeriodicalIF":0.2,"publicationDate":"2022-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47076803","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
J. Ricardo-Garcell, Francia Guadarrama-Celaya, G. Otero-Ojeda, R. Rodríguez-Valdés, L. Aguilar-Fabré, Hebert L. Hernández-Vázquez, P. García-Solís, J. Solís-S, Carlota García, Javier Ávila-Morales, H. Hernández-Montiel
{"title":"Alterations in neurodevelopment in children under 5 years of age in two states of the Mexican Republic","authors":"J. Ricardo-Garcell, Francia Guadarrama-Celaya, G. Otero-Ojeda, R. Rodríguez-Valdés, L. Aguilar-Fabré, Hebert L. Hernández-Vázquez, P. García-Solís, J. Solís-S, Carlota García, Javier Ávila-Morales, H. Hernández-Montiel","doi":"10.24875/rmn.21000075","DOIUrl":"https://doi.org/10.24875/rmn.21000075","url":null,"abstract":"","PeriodicalId":53921,"journal":{"name":"Revista Mexicana de Neurociencia","volume":null,"pages":null},"PeriodicalIF":0.2,"publicationDate":"2022-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41368163","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
P. Carrillo-Mora, Yesenia Lugo Rodríguez, Kenia F. Franyutti-Prado, Marlene A. Rodriguez-Barragan, Nelly G. Cervera-Delgadillo
{"title":"Stimulant drugs to promote the awake state and cognitive performance: Do they really work?","authors":"P. Carrillo-Mora, Yesenia Lugo Rodríguez, Kenia F. Franyutti-Prado, Marlene A. Rodriguez-Barragan, Nelly G. Cervera-Delgadillo","doi":"10.24875/rmn.21000064","DOIUrl":"https://doi.org/10.24875/rmn.21000064","url":null,"abstract":"","PeriodicalId":53921,"journal":{"name":"Revista Mexicana de Neurociencia","volume":null,"pages":null},"PeriodicalIF":0.2,"publicationDate":"2022-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45355283","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
J. Farina, A. Miranda-Arboleda, Pablo A. Lomini, A. Baranchuk
{"title":"Neurological complications of interatrial blocks and Bayes’ syndrome","authors":"J. Farina, A. Miranda-Arboleda, Pablo A. Lomini, A. Baranchuk","doi":"10.24875/rmn.m22000087","DOIUrl":"https://doi.org/10.24875/rmn.m22000087","url":null,"abstract":"","PeriodicalId":53921,"journal":{"name":"Revista Mexicana de Neurociencia","volume":null,"pages":null},"PeriodicalIF":0.2,"publicationDate":"2022-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69051817","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
A. Cervantes-Arriaga, Cynthia Sarabia-Tapia, O. Esquivel-Zapata, Susana López-Alamillo, Etienne Reséndiz-Henriquez, T. Corona, M. Rodríguez‐Violante
Objective: We carried out a cross-sectional study to identify the factors involved in each stage of the diagnosis pathway that may lead to a diagnostic delay in persons with Parkinson’s disease (PD). Materials and Methods: Consecutive patients with PD were included. A questionnaire assessing the recognition of the initial symptoms, pathway to seek attention diagnosis and perception on the diagnostic time and identified barriers was applied. Diagnosis delay was defined as ≥ 12 months between initial recognition of the symptom and the definitive diagnosis of PD. Results: A total of 114 patients (57.9% male) with PD were included in the study. The overall median time of the diagnosis pathway was 14.5 (interquartile range [IQR] 31) months and the longest time in this pathway was between the first medical consultation and the definitive diagnosis of PD, a median of 9 (IQR 14) months. The main appraisal of the first symptom was being “not worried” (48.2%). The mains reasons for seeking medical attention were symptom worsening (42.1%). Patient’s perception on the diagnostic time was reported as very adequate/adequate in 52.7%. Barriers delaying the diagnosis identified included the belief of spontaneous symptoms relief and lack of trust in their doctor. Conclusion: Both the person with PD and the physician play a shared role in the diagnosis of PD. Improving the awareness of the disease, as well as improving medical education on PD, could result in a timely diagnosis.
{"title":"Pitfalls and caveats in the diagnostic pathway of people with Parkinson’s disease","authors":"A. Cervantes-Arriaga, Cynthia Sarabia-Tapia, O. Esquivel-Zapata, Susana López-Alamillo, Etienne Reséndiz-Henriquez, T. Corona, M. Rodríguez‐Violante","doi":"10.24875/rmn.21000041","DOIUrl":"https://doi.org/10.24875/rmn.21000041","url":null,"abstract":"Objective: We carried out a cross-sectional study to identify the factors involved in each stage of the diagnosis pathway that may lead to a diagnostic delay in persons with Parkinson’s disease (PD). Materials and Methods: Consecutive patients with PD were included. A questionnaire assessing the recognition of the initial symptoms, pathway to seek attention diagnosis and perception on the diagnostic time and identified barriers was applied. Diagnosis delay was defined as ≥ 12 months between initial recognition of the symptom and the definitive diagnosis of PD. Results: A total of 114 patients (57.9% male) with PD were included in the study. The overall median time of the diagnosis pathway was 14.5 (interquartile range [IQR] 31) months and the longest time in this pathway was between the first medical consultation and the definitive diagnosis of PD, a median of 9 (IQR 14) months. The main appraisal of the first symptom was being “not worried” (48.2%). The mains reasons for seeking medical attention were symptom worsening (42.1%). Patient’s perception on the diagnostic time was reported as very adequate/adequate in 52.7%. Barriers delaying the diagnosis identified included the belief of spontaneous symptoms relief and lack of trust in their doctor. Conclusion: Both the person with PD and the physician play a shared role in the diagnosis of PD. Improving the awareness of the disease, as well as improving medical education on PD, could result in a timely diagnosis.","PeriodicalId":53921,"journal":{"name":"Revista Mexicana de Neurociencia","volume":null,"pages":null},"PeriodicalIF":0.2,"publicationDate":"2022-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41335023","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Alejandro Checa, Eliana Navas, V. Valencia, Jessica Alcívar
Background: Complications of COVID-19 can include neurological, psychiatric, psychological, and psychosocial sequelae. Little is known about the consequences of COVID-19 on the cognitive functions of patients in the subacute phase of the disease. Objective: The objective of the study was to determine if there is an incidence of cognitive impairment in patients with COVID-19 with mild to moderate symptoms in the remission phase. Method: This is a cross-sectional study conducted between April 2021 and August 2021 at the Eugenio Espejo Hospital in Quito, Ecuador. The Montreal Cognitive Assessment test was applied to COVID-19 patients with mild to moderate symptoms. Results: A total of 50 subjects were recruited, 88% (n = 44) presented cognitive deterioration and only 12% (n = 6) showed a normal score. Conclusions: In our cohort study, patients with COVID-19 with mild-moderate symptoms are at high risk of cognitive impairment. (English) [ FROM AUTHOR] Antecedentes: Las complicaciones de COVID-19 pueden incluir secuelas neurológicas, psiquiátricas, psicológicas y psicosociales. Se sabe poco sobre las consecuencias del COVID-19 en las funciones cognitivas de los pacientes en la fase subaguda de la enfermedad. Objetivo: Determinar si existe incidencia de deterioro cognitivo en pacientes con COVID-19 con síntomas leves a moderados en la fase de remisión. Método: Se trata de un estudio de tipo transversal realizado entre abril de 2021 y agosto de 2021 en el Hospital Eugenio Espejo de Quito, Ecuador. Se aplicó el MoCA test a los pacientes con COVID-19 con síntomas de leve a moderado. Resultados: Un total de 50 sujetos fueron reclutados, el 88% (n = 44) presentó deterioro cognitivo y apenas el 12% (n = 6) evidenció una puntuación normal. Conclusiones: En nuestro estudio de cohorte los pacientes con COVID-19 con sintomatología leve-moderada tienen un alto riesgo de presentar deterioro cognitivo. (Spanish) [ FROM AUTHOR] Copyright of Revista Mexicana de Neurociencia is the property of Academia Mexicana de Neurologia and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full . (Copyright applies to all s.)
{"title":"Cognitive impairment in people with COVID-19 with mild-moderate symptoms in Ecuador","authors":"Alejandro Checa, Eliana Navas, V. Valencia, Jessica Alcívar","doi":"10.24875/rmn.21000060","DOIUrl":"https://doi.org/10.24875/rmn.21000060","url":null,"abstract":"Background: Complications of COVID-19 can include neurological, psychiatric, psychological, and psychosocial sequelae. Little is known about the consequences of COVID-19 on the cognitive functions of patients in the subacute phase of the disease. Objective: The objective of the study was to determine if there is an incidence of cognitive impairment in patients with COVID-19 with mild to moderate symptoms in the remission phase. Method: This is a cross-sectional study conducted between April 2021 and August 2021 at the Eugenio Espejo Hospital in Quito, Ecuador. The Montreal Cognitive Assessment test was applied to COVID-19 patients with mild to moderate symptoms. Results: A total of 50 subjects were recruited, 88% (n = 44) presented cognitive deterioration and only 12% (n = 6) showed a normal score. Conclusions: In our cohort study, patients with COVID-19 with mild-moderate symptoms are at high risk of cognitive impairment. (English) [ FROM AUTHOR] Antecedentes: Las complicaciones de COVID-19 pueden incluir secuelas neurológicas, psiquiátricas, psicológicas y psicosociales. Se sabe poco sobre las consecuencias del COVID-19 en las funciones cognitivas de los pacientes en la fase subaguda de la enfermedad. Objetivo: Determinar si existe incidencia de deterioro cognitivo en pacientes con COVID-19 con síntomas leves a moderados en la fase de remisión. Método: Se trata de un estudio de tipo transversal realizado entre abril de 2021 y agosto de 2021 en el Hospital Eugenio Espejo de Quito, Ecuador. Se aplicó el MoCA test a los pacientes con COVID-19 con síntomas de leve a moderado. Resultados: Un total de 50 sujetos fueron reclutados, el 88% (n = 44) presentó deterioro cognitivo y apenas el 12% (n = 6) evidenció una puntuación normal. Conclusiones: En nuestro estudio de cohorte los pacientes con COVID-19 con sintomatología leve-moderada tienen un alto riesgo de presentar deterioro cognitivo. (Spanish) [ FROM AUTHOR] Copyright of Revista Mexicana de Neurociencia is the property of Academia Mexicana de Neurologia and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full . (Copyright applies to all s.)","PeriodicalId":53921,"journal":{"name":"Revista Mexicana de Neurociencia","volume":null,"pages":null},"PeriodicalIF":0.2,"publicationDate":"2022-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43032814","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Objective: We carried out a cross-sectional study to identify the factors involved in each stage of the diagnosis pathway that may lead to a diagnostic delay in persons with Parkinson’s disease (PD). Materials and Methods: Consecutive patients with PD were included. A questionnaire assessing the recognition of the initial symptoms, pathway to seek attention diagnosis and perception on the diagnostic time and identified barriers was applied. Diagnosis delay was defined as ≥ 12 months between initial recognition of the symptom and the definitive diagnosis of PD. Results: A total of 114 patients (57.9% male) with PD were included in the study. The overall median time of the diagnosis pathway was 14.5 (interquartile range [IQR] 31) months and the longest time in this pathway was between the first medical consultation and the definitive diagnosis of PD, a median of 9 (IQR 14) months. The main appraisal of the first symptom was being “not worried” (48.2%). The mains reasons for seeking medical attention were symptom worsening (42.1%). Patient’s perception on the diagnostic time was reported as very adequate/adequate in 52.7%. Barriers delaying the diagnosis identified included the belief of spontaneous symptoms relief and lack of trust in their doctor. Conclusion: Both the person with PD and the physician play a shared role in the diagnosis of PD. Improving the awareness of the disease, as well as improving medical education on PD, could result in a timely diagnosis. Abstract Background: Complications of COVID-19 can include neurological, psychiatric, psychological, and psychosocial sequelae. Little is known about the consequences of COVID-19 on the cognitive functions of patients in the subacute phase of the disease. Objective: The objective of the study was to determine if there is an incidence of cognitive impairment in patients with COVID-19 with mild to moderate symptoms in the remission phase. Method: This is a cross-sectional study conducted between April 2021 and August 2021 at the Eugenio Espejo Hospital in Quito, Ecuador. The Montreal Cognitive Assessment test was applied to COVID-19 patients with mild to moderate symptoms. Results: A total of 50 subjects were recruited, 88% (n = 44) presented cognitive deterioration and only 12% (n = 6) showed a normal score. Conclusions: In our cohort study, patients with COVID-19 with mild-moderate symptoms are at high risk of cognitive impairment. Abstract Objective: The objective of the study is to identify the risk and protective factors associated with Parkinson’s disease (PD) in inhabitants of Yucatan. Methods: Case control study. A questionnaire with the main risk and protective factors for PD described in the literature was applied to cases and controls. Results: The sample consisted of 85 cases and 124 controls. In the univariate logistic regression analyzes, it was found that the following factors were significantly associated with a higher risk of developing PD: family history of PD (OR = 5.28, p
{"title":"New era of the Revista Mexicana de Neurociencia","authors":"A. Arauz, L. Dávila-Maldonado","doi":"10.24875/rmn.m22000090","DOIUrl":"https://doi.org/10.24875/rmn.m22000090","url":null,"abstract":"Objective: We carried out a cross-sectional study to identify the factors involved in each stage of the diagnosis pathway that may lead to a diagnostic delay in persons with Parkinson’s disease (PD). Materials and Methods: Consecutive patients with PD were included. A questionnaire assessing the recognition of the initial symptoms, pathway to seek attention diagnosis and perception on the diagnostic time and identified barriers was applied. Diagnosis delay was defined as ≥ 12 months between initial recognition of the symptom and the definitive diagnosis of PD. Results: A total of 114 patients (57.9% male) with PD were included in the study. The overall median time of the diagnosis pathway was 14.5 (interquartile range [IQR] 31) months and the longest time in this pathway was between the first medical consultation and the definitive diagnosis of PD, a median of 9 (IQR 14) months. The main appraisal of the first symptom was being “not worried” (48.2%). The mains reasons for seeking medical attention were symptom worsening (42.1%). Patient’s perception on the diagnostic time was reported as very adequate/adequate in 52.7%. Barriers delaying the diagnosis identified included the belief of spontaneous symptoms relief and lack of trust in their doctor. Conclusion: Both the person with PD and the physician play a shared role in the diagnosis of PD. Improving the awareness of the disease, as well as improving medical education on PD, could result in a timely diagnosis. Abstract Background: Complications of COVID-19 can include neurological, psychiatric, psychological, and psychosocial sequelae. Little is known about the consequences of COVID-19 on the cognitive functions of patients in the subacute phase of the disease. Objective: The objective of the study was to determine if there is an incidence of cognitive impairment in patients with COVID-19 with mild to moderate symptoms in the remission phase. Method: This is a cross-sectional study conducted between April 2021 and August 2021 at the Eugenio Espejo Hospital in Quito, Ecuador. The Montreal Cognitive Assessment test was applied to COVID-19 patients with mild to moderate symptoms. Results: A total of 50 subjects were recruited, 88% (n = 44) presented cognitive deterioration and only 12% (n = 6) showed a normal score. Conclusions: In our cohort study, patients with COVID-19 with mild-moderate symptoms are at high risk of cognitive impairment. Abstract Objective: The objective of the study is to identify the risk and protective factors associated with Parkinson’s disease (PD) in inhabitants of Yucatan. Methods: Case control study. A questionnaire with the main risk and protective factors for PD described in the literature was applied to cases and controls. Results: The sample consisted of 85 cases and 124 controls. In the univariate logistic regression analyzes, it was found that the following factors were significantly associated with a higher risk of developing PD: family history of PD (OR = 5.28, p","PeriodicalId":53921,"journal":{"name":"Revista Mexicana de Neurociencia","volume":null,"pages":null},"PeriodicalIF":0.2,"publicationDate":"2022-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48070618","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：